Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients with Chronic Hepatitis B
NCTID
NCT06680232
(View at clinicaltrials.gov)
Description
This is a Phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and antiviral activity of PBGENE-HBV in adult participants with chronic hepatitis B.
(Show More)
Development Status
Active
Indication
Chronic Hepatitis B
Disease Ontology Term
DOID:2043
Compound Name
PBGENE-HBV
Sponsor
Precision BioSciences, Inc.
Funder Type
Industry
Recruitment Status
Recruiting
Enrollment Count
45
Results Posted
Not Available
Therapy Information
Target Gene/Variant
HBV DNA
Therapy Type
Gene editing
Therapy Route
In-vivo
Mechanism of Action
Gene inactivation
Route of Administration
Intravenous
Drug Product Type
LNP
Target Tissue/Cell
Delivery System
Lipid encapsulation
Vector Type
LNP
Editor Type
ARCUS
Dose 1
0.25mg/kg
Dose 2
Undisclosed medium/high doses
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Phase1
Submit Date
2024-10-24
Completion Date
2026-12
Last Update
2025-02-10
Participation Criteria
Eligible Age
18 Years - 70 Years
Standard Ages
Adult, Older adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
3
Locations
New Zealand,Hong Kong,Moldova, Republic of
Regulatory Information
Has US IND
True
FDA Designations
Fast Track
Recent Updates
IND cleared by FDA in March 2025
Resources/Links
News and Press Releases
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
Precision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis B
Precision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical Trial
Preclinical Publications
(Poster) Preclinical safety data for PBGENE-HBV gene editing program supports advancement to clinical trials as a potentially curative treatment for chronic hepatitis B
(Poster) Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy - AASLD 2023